FibroBiologics (FBLG) Total Non-Current Liabilities (2022 - 2024)
FibroBiologics (FBLG) posted quarterly Total Non-Current Liabilities of $13.7 million for Q4 2024, up 29.76% year-over-year from $10.6 million in Q1 2024, and up 182.97% on a QoQ basis from $4.8 million in Q3 2024.
FibroBiologics (FBLG) Total Non-Current Liabilities (2022 - 2024) Analysis & Trends
FibroBiologics has reported Total Non-Current Liabilities for 3 years, with the latest figure at $13.7 million in Q4 2024.
- Total Non-Current Liabilities for Q4 2024 came in at $13.7 million, up 29.76% year-over-year; the trailing twelve-month figure through Dec 2024 was $13.7 million (up 29.76% YoY), and the FY2024 annual result was $13.7 million, up 29.76% from the prior year.
- Total Non-Current Liabilities grew to $13.7 million in Q4 2024, from $4.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $15.3 million in Q1 2024 and troughed at -$2.6 million in Q2 2023.
- A 3-year average of $6.8 million and a median of $6.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The largest YoY upside for Total Non-Current Liabilities was 3396.33% in 2024 against a maximum downside of 29.76% in 2024.
- A 3-year view of Total Non-Current Liabilities shows it stood at $6.2 million in 2022, then jumped by 69.13% to $10.6 million in 2023, then increased by 29.76% to $13.7 million in 2024.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $13.7 million in Q4 2024, $4.8 million in Q3 2024, and $6.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 13.71 Mn |
| Sep 30, 2024 | 4.85 Mn |
| Jun 30, 2024 | 6.49 Mn |
| Mar 31, 2024 | 15.26 Mn |
| Dec 31, 2023 | 10.57 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -463,000.00 |
| Dec 31, 2022 | 6.25 Mn |